Impel NeuroPharma Closes $67.5 Million Series D Financing

“We are excited to have co-led this financing round with KKR and look forward to helping Impel reach its goals as the Company progresses the development of these novel investigative therapies,” said Dr. Mittendorff. “Norwest shares in Impel’s belief that the Company’s pipeline has the potential to bring important new treatments to the market for the CNS community.”

“We are thrilled to contribute to the development of innovative solutions that may enhance the lives of patients with CNS disorders,” said Mr. Satvat. “Impel’s proprietary, novel platform has the potential to transform intranasal drug delivery, significantly improving the range of treatment options for people living with acute migraine, acute agitation and Parkinson’s disease.”

Impel’s products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD(TM), device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner.

SOURCE Impel NeuroPharma, Inc.